News Breaks |
|
|
| March 18, 2013 |
| 07:09 EDT |  | LGND, SPPI | Ligand Pharmaceuticals deal positive, says Cantor
After Ligand Pharmaceuticals (LGND) announced a license and global supply agreement with Spectrum Pharmaceuticals (SSPI) on Captisol-enabled Melphalan for the treatment of multiple myeloma, Cantor believes the deal is "attractive" for Ligand. The firm, which maintains a Hold rating on Ligand, indicates that it is close to upgrading the stock, but is not doing so because it is still concerned about the company's Promacta generic filer announcement. |
|
|
News For LGND;SPPI From The Last 14 Days Check below for free stories on LGND;SPPI the last two weeks. |
|
|
| May 15, 2013 |
| 19:34 EDT |  | SPPI | On The Fly: After Hours Movers
 Subscribe for More Information |
|
| 11:16 EDT |  | SPPI | Options with decreasing implied volatility: RAX CSC SPPI MBI PANL
|
|
| 11:06 EDT |  | LGND | Ligand Pharmaceuticals management to meet with Roth Capital
Subscribe for More Information |
|
| May 9, 2013 |
| 07:09 EDT |  | SPPI | Spectrum reports Q1 EPS (5c), consensus (16c)
Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014. |
|
| May 8, 2013 |
| 16:10 EDT | | LGND | Ligand Pharmaceuticals sees Q2 EPS 3c-5c, consensus 4c
Sees Q2 revenue $9.0M-$9.5M, consensus $9.10M. |
|
| 16:08 EDT | | LGND | Ligand Pharmaceuticals reaffirms 2013 EPS view 47c-51c, consensus 46c
Subscribe for More Information |
|
| 16:07 EDT | | LGND | Ligand Pharmaceuticals reports Q1 adjusted EPS 16c, consensus 9c
Subscribe for More Information |
|
|
|
|
|
